 SAN DIEGO, Feb. 17, 2022 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Companys solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer mCRPC. These data are being presented today at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium ASCO GU in a poster presentation entitled, Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer mCRPC. 